Among registered obesity trials reviewed, drug repurposing was common (22.2%), notably involving liraglutide.
In plain wordsIn a review of registered obesity trials, drug repurposing accounted for 22.2% of the trial landscape and notably included liraglutide.
- Peptide
- Liraglutide
- Outcome
- Not applicableDrug repurposing among registered obesity trials
- Study
n: not reported in source
- Outcome group
- Patterns of use · Pharmacology
Measurements
- Drug repurposing
- 22.2%
- registered obesity trials
Source sentences
Drug repurposing was common (22.2%), notably involving semaglutide and liraglutide, originally approved for type 2 diabetes.
2 context sentences(design, population, supporting numbers)
We conducted a systematic review of clinical trials registered on ClinicalTrials.gov between October 2019 and October 2024, focusing on pharmacological interventions for obesity from early exploratory stages to Phase 3.
A total of 275 eligible trials were identified and analyzed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.